Arima Genomics Reports New Data at ASH 2025 Supporting More Complete Rearrangement Profiling in DLBCL With Hi-C Technology Used in Aventa Lymphoma

Largest DLBCL cohort studied to date with a genome-wide structural assay highlights the limitations of target-limited FISH and the added diagnostic context of Hi-C from FFPE tissue

Excerpt from the Press Release:.

CARLSBAD, Calif.–(BUSINESS WIRE)–Arima Genomics, Inc., a company leveraging whole-genome sequence and structure information to provide comprehensive cancer therapy selection insights, today announced new data to be presented at the 2025 American Society of Hematology (ASH) Annual Meeting and Exposition taking place in Orlando, FL from December 6–9, 2025.

In the largest cohort to date comparing the Hi-C–based method for genome-wide analysis of fusions and rearrangements used in the Aventa™ Lymphoma test with conventional fluorescence in situ hybridization (FISH) in diffuse large B-cell lymphoma (DLBCL), investigators showed that the Hi-C assay identified additional clinically relevant rearrangements that routine FISH panels missed, and did so with higher sensitivity for key biomarkers associated with diagnosis and prognosis.

The retrospective study evaluated FFPE tumor samples from 159 patients with DLBCL uniformly treated with R-CHOP. All cases had previously undergone FISH testing for MYC, BCL2 and BCL6 rearrangements. Using the same Hi-C sequencing method that underlies the clinically available Aventa Lymphoma test, researchers compared genome-wide structural rearrangement calls to clinical FISH results and assessed the potential clinical impact of discordant findings.

Click the button below to read the entire Press Release:

Continue Reading The Press Release